Vivo Capital LLC decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 5.5% during the first quarter, HoldingsChannel reports. The firm owned 2,046,832 shares of the biotechnology company’s stock after selling 120,000 shares during the period. Ascendis Pharma A/S makes up approximately 24.0% of Vivo Capital LLC’s holdings, making the stock its biggest holding. Vivo Capital LLC’s holdings in Ascendis Pharma A/S were worth $240,912,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quantamental Technologies LLC bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $25,000. Lindbrook Capital LLC bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at about $54,000. Citigroup Inc. bought a new position in shares of Ascendis Pharma A/S during the first quarter valued at about $70,000. NumerixS Investment Technologies Inc bought a new position in shares of Ascendis Pharma A/S during the first quarter valued at about $94,000. Finally, Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S in the first quarter worth about $113,000.

ASND traded up $2.47 on Wednesday, hitting $121.27. The company had a trading volume of 9,584 shares, compared to its average volume of 349,645. The company has a debt-to-equity ratio of 0.02, a current ratio of 22.32 and a quick ratio of 22.32. Ascendis Pharma A/S has a 52-week low of $53.21 and a 52-week high of $133.96. The firm has a market capitalization of $5.19 billion, a PE ratio of -32.32 and a beta of 0.77.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, April 3rd. The biotechnology company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 901.89% and a negative return on equity of 34.64%. The business had revenue of $12.00 million during the quarter. Analysts expect that Ascendis Pharma A/S will post -5.07 EPS for the current fiscal year.

Several research firms recently issued reports on ASND. Zacks Investment Research cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. BidaskClub raised Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $185.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 18th. Wedbush raised their target price on Ascendis Pharma A/S from $219.00 to $223.00 and gave the stock an “outperform” rating in a research note on Monday, June 3rd. Finally, Canaccord Genuity raised their target price on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $137.22.

TRADEMARK VIOLATION NOTICE: “Vivo Capital LLC Sells 120,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2019/06/12/vivo-capital-llc-sells-120000-shares-of-ascendis-pharma-a-s-nasdaqasnd.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Trading based on a resistance level

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.